Alvogen and Viatris Team Up to Prepare Korean Launch of Vascepa, an Option After Statin Therapy
- Input
- 2026-11-09 08:31:43
- Updated
- 2026-11-09 08:31:43

[Financial News] Alvogen Korea is partnering with Viatris Korea to commercialize Vascepa, a treatment for patients at high cardiovascular risk, in Korea.
Alvogen Korea said on the 9th that it had signed an agreement with Viatris Korea for the exclusive distribution and joint promotion in Korea of the prescription drug Vascepa Soft Capsules 998 mg (active ingredient: icosapent ethyl). Viatris Korea is the Korean subsidiary of global healthcare company Viatris.
Under the agreement, Alvogen Korea will hold the product approval for Vascepa and lead all aspects of its commercialization in Korea, including brand strategy, product supply, regulatory matters and reimbursement. Viatris Korea will handle exclusive distribution in Korea. The two companies will jointly conduct sales and promotional activities.
Vascepa received product approval in Korea last May. The specific launch date will be determined in light of progress toward reimbursement listing and other factors.
Vascepa is a single-ingredient formulation composed solely of icosapent ethyl (IPE), and is distinguished by containing only eicosapentaenoic acid (EPA) among omega-3 fatty acids. In Korea, it was approved to reduce the risk of cardiovascular events in adults at high cardiovascular risk whose triglyceride levels remain at 150 mg/dL or higher despite statin treatment. Eligible patients are those with a history of cardiovascular disease, or those with diabetes and at least one cardiovascular risk factor.
Its efficacy was confirmed in the large-scale REDUCE-IT clinical trial. Among the 8,179 high-risk cardiovascular patients receiving statin treatment in the study, the incidence of a first major cardiovascular event was 17.2% in the Vascepa group and 22.0% in the placebo group. This represented a 25% reduction in the risk of an event compared with placebo (HR 0.75; 95% CI 0.68-0.83). The primary composite endpoint included death from cardiovascular disease, nonfatal myocardial infarction or stroke, coronary revascularization, and hospitalization for unstable angina.
Lee Uk-se, president of Alvogen Korea, said, "We expect this collaboration to provide a new treatment option for patients in Korea who need cardiovascular risk management." He added, "Drawing on the strengths and capabilities of both companies, we will prepare thoroughly for the launch in Korea and work to ensure a stable product supply, contributing to the management of patients' cardiovascular disease."
Bill Schuster, president of Viatris Korea, said, "Viatris has contributed to meeting patients' diverse treatment needs through its longstanding experience and broad portfolio in cardiovascular disease." He added, "Through this collaboration, we will further strengthen our cardiovascular disease portfolio and work to broaden patients' access to the treatment options they need."
Alvogen Korea is an affiliate of global pharmaceutical company Lotus Group. Its portfolio spans prescription and over-the-counter medicines, including treatments for obesity, central nervous system disorders, kidney disease and cardiovascular disease.
[email protected] Jung Myung-jin, Reporter